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Summary The association between serum levels of alpha,-antitrypsin (a,AT) at the time of diagnosis and
survival was studied in a group of 78 patients with confirmed hepatocellular carcinoma (HCC). All 78 patients
were followed until the time of death, which occurred in all instances from HCC, with a median time of
6 months and a range of 1-117 months. Cox's proportional hazards model was utilised in the analysis
controlling for sex, age, HBsAg status and logarithmically transformed values of a-fetoprotein (ax-FP). Older
patients and patients positive for HBsAg have suggestively higher fatality rates (0.05 <P <0.10) whereas in
these data sex and AFP levels were not important prognostic factors. Increased levels of serum a xEAT at the
time of diagnosis of HCC were statistically significantly (P <0.05) related with shorter survival, patients with
higher serum a,AT by 200 mg 100 ml-' having an expected survival time shorter by about 25%.
a,-Antitrypsin (o,AT) is the main protease inhibitor in
human serum and its most important biological function is to
inactivate a variety of proteolytic enzymes, particularly
leukocyte elastase (Harpel, 1983; Cohen, 1986). Individuals
who are homozygous for the Z allele are at an increased risk
for hepatocellular carcinoma (HCC) (Eriksson et al., 1986),
but there is no convincing evidence that individuals who are
heterozygous for the Z allelle, and other alleles associated
with mjAT deficiency, are over-represented among cases of
HCC (Govindarajan et al., 1981; Sparos et al., 1984; Erik-
sson, 1985; Marwick et al., 1985; Schneider et al., 1986).
Interestingly, several authors have confirmed the observation
of Kew et al. (1978) that HCC cases have elevated levels of
serum a,AT, an increase which is found across several a,AT
phenotypes (Chio & Oon, 1979; Matsuzaki et al., 1981). In
1984 we reported the results of a relatively large
epidemiological study in Greece exploring, among other
issues, the association between a,AT levels and HCC, by
hepatitis B virus (HBV) serological status (Sparos et al.,
1984). Since then, we have been able to follow, until the time
of death, 78 out of the 80 cases with HCC included in that
study, and we report here the findings concerning the
association between serum levels of a,AT and survival of
these patients.
Patients and methods
In the original study (Trichopoulos et al., 1978) 80 HCC
patients were included, but two of them were lost to follow-
up. The disease was histologically confirmed in 47 cases and
by diagnostically high a-fetoprotein (a-FP) values in the
remaining 31 cases. All patients were Caucasian, of Greek
nationality and residence, hospitalised in one of eight large
hospitals in Athens during a 15-month period in 1976 and
1977. Among these patients 67 (87%) were males, and the
average age was 63 years. Hepatitis B serological markers and
a-FP levels were determined by radioimmunoassay
(Trichopoulos et al., 1978, 1980). Serum levels and
phenotypes of a,AT were determined by radial
immunodiffusion and electrofocusing in acrylamide gel,
respectively (Vesterberg, 1973; Chapuis-Cellier, 1975). All
xjAT determinations were performed in the Department of
Clinical Biochemistry of the Hospital 'Edouard Herriot' in
Lyon, France (Sparos et al., 1984). All serologic determina-
tions refer to the time of the HCC diagnosis and were
performed blindly.
An effort was made, by ourselves, to follow regularly all
HCC patients, but two of them were lost immediately after
their first hospitalisation. The remaining 78 were followed by
letters, telephone calls and, eventually, personal visits until
their death, which occurred at times between 25 days and
117 months after diagnosis. All these patients died from
HCC, according to their relatives, doctors and death
certificates.
The statistical analysis was done by Cox's proportional
hazards model (Cox, 1972), using survival time (there were
no censored observations), sex (male = 1, female = 2), age (in
decades), HBsAg status (negative = 1, positive = 2), serum
a,AT levels (in 100mg 100 ml-') and serum a-FP levels (in
ng ml-' after log transformation) as model variables. Cox's
model allows the estimation of the patients' instantaneous
fatality rate ratio (and associated confidence intervals), con-
trasting two particular values of any particular variable,
while controlling for the potential confounding effects of the
other prognostic risk factors in the model. In the present
situation, in which there are no censored observations, Cox's
model is conceptually equivalent to standard multiple regres-
sion models, with survival time as dependent variable. Cox's
model was chosen because it generates epidemiologically
interpretable parameters like the rate ratio, and is frequently
utilised in exposure based studies and clinical follow-up
investigations.
Results
Among the 78 HCC cases, 39 (50%) were positive for
HBsAg. The distribution of the 78 HCC cases by a,AT
phenotypes was as follows: MIMI 37, M1M2 6, MIM3 23,
M2M2 5, M2M3 4, M3M3 0 and other 3. The mean value of
axAT was 616 mg 100ml-' with 95% confidence intervals
(CI) 579-652mg 100lml'; the geometric mean value of
a-FP was 8,268 ng ml- ' with 95% CI, 3,791 - 18,034 ng ml- '.
The median survival time of HCC patients was 6 months,
with a range from 25 days to 117 months.
Table I summarises the results derived from the appli-
cation of the proportional hazards model on the survival
data of HCC patients.
There is evidence that the fatality rate from HCC is higher
among older persons and among patients who are positive
for HBsAg, whereas neither sex nor a-FP levels are prognos-
tic indicators in these series. There is a moderately strong
positive correlation between serum levels ofa,AT and fatality
rate from HCC, an increase of 100 mg 100 ml- ' correspond-
ing to an increase of death rate of 15% (P-0.05).
Discussion
a,-Antitrypsin is under genetic control, and more than 30
codominant alleles at a single chromosomal locus have been
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Table I Survival of 78 patients with HCC
95% confidence P
Variable Category Rate ratio Unit interval (two-tailed)
Sex male Baseline n.a.a (0.48-1.87) >0.50
female 0.95
Age continuous 1.27 10 years (0.98-1.65) -0.07
HBsAg negative Baseline n.a. (0.93-2.81) -0.09
positive 1.61
a-FT continuous 0.99 1 log unit (0.83-1.17) >0.50
(10-fold
increase)
a,AT continuous 1.15 100mg 100 ml-' (1.01-1.32) <0.05
Proportional hazards model derived fatality rate ratios associated with serum levels of a,AT and
other variables. All rates ratios are mutually adjusted. aNot applicable.
identified (Cox, 1978; Morse, 1978; Kuhnl & Spielmann,
1979; Buffone et al., 1983; Dykes et al., 1984). The associa-
tion between a,AT and HCC is complex and intriguing, and
may reflect both the pathophysiological role of a,AT (Eriks-
son, 1985; Garver et al., 1986) and its production by the liver
(Glasgow et al., 1982). However, there have been no reports
concerning the prognostic significance of a,AT in HCC,
although Ishikura et al. (1986) have speculated that the poor
prognosis of hepatoid adenocarcinomas of the stomach may
be accounted for, in part, by the increased levels of serum
axAT frequently noted in these tumours.
The results of the present study indicate that serum levels
ofa,AT represent an important prognostic factor for survival
among patients with HCC. Thus, as a further example, a
difference of serum ,1AT of 200 mg 00 ml-' implies a
difference of survival time of 25%, and a difference of serum
axAT of 400 mg 100 ml-' implies a difference of survival time
of more than 40%. It should be noted that the prognostic
value of serum axAT is considerably more important than
that of serum a-FP; in fact, in the present study, the associa-
tion of serum a-FP with survival controlling for the serum
ajAT, was statistically non-significant and clinically unimpor-
tant.
The underlying pathogenesis of the reported association is
not clear, but there is some evidence that increased levels of
serum axAT may be an indicator of poor prognosis in other
malignancies, including breast cancer (Thompson et al., 1983)
and cancer of the pancreas (Trichopoulos et al., submitted
for publication). The association of serum a1AT with survival
may reflect its role as an acute phase protein, since these
proteins appear to have prognostic significance in several
cancers, possibly through a mediating mechanisms involving
suppression of cellular immunity (Baskies et al., 1980;
Thompson et al., 1983; Ishikura et al., 1986). However, a
more specific role of axAT in the pathogenesis and natural
history of HCC cannot be excluded, given the numerous
special links between a,AT and HCC (Sparos et al., 1984;
Eriksson et al., 1986).
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